Welcome to our dedicated page for Moderna news (Ticker: MRNA), a resource for investors and traders seeking the latest updates and insights on Moderna stock.
Moderna, Inc. (NASDAQ: MRNA) is a biotechnology company focused on mRNA medicines, with multiple approved vaccines and a broad clinical pipeline. The MRNA news page on Stock Titan aggregates company announcements, investor updates and regulatory developments so readers can follow how Moderna’s strategy and pipeline progress translate into real-world events.
Investors and observers can use this feed to track commercial updates on products such as Spikevax, mRESVIA and mNEXSPIKE, along with developments in late-stage respiratory programs like the seasonal influenza vaccine mRNA-1010, the flu/COVID combination vaccine mRNA-1083 and the Norovirus vaccine candidate mRNA-1403. News items often cover regulatory submissions and opinions from agencies including the U.S. Food and Drug Administration, the European Medicines Agency, Health Canada and others.
The page also surfaces pipeline and clinical trial news in oncology and rare diseases, including updates on mRNA-4157 (intismeran autogene), mRNA-4359, mRNA-3927 for propionic acidemia and mRNA-3705 for methylmalonic acidemia. Announcements related to partnerships, such as CEPI’s funding commitment for the H5 pandemic influenza vaccine candidate mRNA-1018, appear here as well.
In addition, the MRNA news feed includes financial results, guidance and capital structure updates, such as quarterly earnings releases, multi-year financial frameworks and information on facilities like the $1.5 billion credit agreement. Corporate items, including participation in healthcare conferences, Analyst Day presentations and shareholder meeting outcomes, are also reflected.
By reviewing this consolidated news stream, readers can see how Moderna’s respiratory vaccine franchise, oncology and rare disease programs, manufacturing expansion and financing decisions evolve over time, all based on the company’s own disclosures and related announcements.
Moderna (Nasdaq: MRNA) and Uber (NYSE: UBER) have announced a partnership to enhance COVID-19 vaccine uptake. The collaboration will begin with providing vaccine safety information through Uber's app and will explore options like in-app ride scheduling for immunization appointments. Uber previously committed to offering 10 million free or discounted rides to facilitate access to vaccines, especially in underserved communities. Both companies aim to expand this initiative globally, reinforcing vaccine education and accessibility efforts.
Moderna (Nasdaq: MRNA) has appointed José M. Vega, M.D. as its new Chief Safety Officer as of January 11, 2021. Dr. Vega, who brings extensive experience from Merck and Amgen, will oversee safety and pharmacovigilance to ensure high standards of patient safety. His previous roles included leading a global team at Merck and holding significant positions at Amgen. This strategic hire is expected to support Moderna's growth and its commitment to delivering transformative mRNA medicines.
Moderna, Inc. (Nasdaq: MRNA) has received authorization from Swissmedic for its COVID-19 Vaccine in Switzerland. This milestone follows a rigorous examination of data from its Phase 3 clinical study. The Swiss Federal Government has ordered 7.5 million doses, with initial deliveries expected soon. Moderna's COVID-19 vaccine is already authorized in numerous countries, including the U.S. and EU, with ongoing applications under review globally. This approval marks a significant step in Moderna's efforts to combat the COVID-19 pandemic.
Moderna (Nasdaq: MRNA) is actively expanding its innovative vaccine pipeline following the success of its COVID-19 vaccine. The company has announced three new mRNA vaccine candidates targeting seasonal flu, HIV, and the Nipah virus. Additionally, it is broadening its respiratory syncytial virus (RSV) vaccine program to include older adults. CEO Stéphane Bancel highlighted the achievements of 2020 as a pivotal moment for Moderna, boosting confidence in pursuing more ambitious vaccine programs. With 24 mRNA candidates across five therapeutic areas, 13 are currently in clinical stages.
Moderna (Nasdaq: MRNA) received approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for its COVID-19 vaccine under Regulation 174. This temporary authorization is based on recommendations from the UK Commission on Human Medicines, allowing supply in Great Britain. The UK government has confirmed an additional purchase of 10 million doses, totaling 17 million doses. This marks the fifth jurisdiction to authorize the vaccine, and the first deliveries are expected early in 2021.
Moderna, Inc. (Nasdaq: MRNA) announces the appointment of Corinne Le Goff as Chief Commercial Officer, effective January 19, 2021. Le Goff, a seasoned executive from Amgen, will join Moderna's Executive Committee and report to CEO Stéphane Bancel. Her extensive experience includes leadership roles at Amgen, Roche, Sanofi, and Pfizer. Bancel emphasized Le Goff's strategic importance as Moderna shifts to a commercial organization, particularly during the launch of its COVID-19 vaccine and its upcoming CMV vaccine study. Moderna is advancing mRNA science for transformative medicines.
Moderna, Inc. (Nasdaq: MRNA) has received a conditional marketing authorization from the European Commission for its COVID-19 vaccine, allowing widespread vaccination in the EU. This follows recommendations from the European Medicines Agency (EMA) and marks the fourth authorization for the vaccine globally, after the U.S., Canada, and Israel. The EU's confirmed order commitment has increased to 160 million doses. Initial deliveries are expected to commence next week. Moderna highlights its role in tackling the pandemic through its innovative mRNA technology.
Moderna (Nasdaq: MRNA) announced that Israel’s Ministry of Health has authorized the import of its COVID-19 Vaccine. This marks the vaccine's third regulatory approval, following the U.S. and Canada. Moderna has secured a contract to supply 6 million doses, with deliveries expected to start soon. The decision is based on comprehensive scientific evidence, including data from its Phase 3 clinical study. The vaccine is currently under review for additional authorizations in various countries, including the EU and the UK.
Moderna (Nasdaq: MRNA) has increased its global production estimate for the COVID-19 Vaccine from 500 million to 600 million doses for 2021. The company aims to scale production to potentially 1 billion doses, expecting 100 million doses available in the U.S. by Q1 2021 and a total of 200 million by the end of Q2 2021. So far, approximately 18 million doses have been supplied to the U.S. government. Moderna has partnerships for production and has secured contracts for 200 million doses with the U.S. and 40 million with Canada.
Moderna, Inc. (Nasdaq: MRNA) will present an update on its mRNA development pipeline at the 39th annual J.P. Morgan Healthcare Conference. CEO Stéphane Bancel's presentation is scheduled for January 11, 2021, at 4:30 p.m. ET, accessible via a live webcast on Moderna's investor website. The company continues to advance mRNA science for various diseases through strategic collaborations, including partnerships with AstraZeneca, Merck, and DARPA. Moderna has been recognized as a leading biopharmaceutical employer by Science for six consecutive years.
FAQ
What is the current stock price of Moderna (MRNA)?
What is the market cap of Moderna (MRNA)?
